Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
10.1182/blood-2013-06-511592
Saved in:
Main Authors: | Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.-W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M., Hochhaus, A. |
---|---|
Other Authors: | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE |
Format: | Article |
Published: |
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/128648 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
by: Hagop Kantarjian, et al.
Published: (2018) -
Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand
by: Wantanee Kulpeng, et al.
Published: (2018) -
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
by: Giuseppe Saglio, et al.
Published: (2018) -
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance
by: Zhang, M., et al.
Published: (2016) -
Cell-based proteome profiling of potential Dasatinib targets by use of affinity-based probes
by: Shi, H., et al.
Published: (2014)